DUSA Levulan
Executive Summary
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet June 3 to discuss aminolevulinic acid for the treatment of multiple precancerous actinic keratoses of the face and scalp, the company said. The NDA for the topical, light-sensitive, photodynamic therapy compound was submitted in July 1998